|
gptkbp:instanceOf
|
gptkb:analgesic
gptkb:drug
gptkb:antipyretic
|
|
gptkbp:ATCCode
|
N02BE01
|
|
gptkbp:bioavailability
|
63–89% (oral)
|
|
gptkbp:brand
|
gptkb:Tylenol
gptkb:Acetaminophen
gptkb:Panadol
|
|
gptkbp:CASNumber
|
103-90-2
|
|
gptkbp:category
|
gptkb:antipyretic
non-opioid analgesic
essential medicine
|
|
gptkbp:chemicalFormula
|
C8H9NO2
|
|
gptkbp:commonDosageForm
|
gptkb:sugar
gptkb:tablet
capsule
injection
suppository
|
|
gptkbp:contraindication
|
severe liver disease
|
|
gptkbp:discoveredBy
|
gptkb:Harmon_Northrop_Morse
|
|
gptkbp:discoveredIn
|
1877
|
|
gptkbp:eliminationHalfLife
|
1–4 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:foundIn
|
combination drugs
|
|
gptkbp:halfLife
|
1–4 hours (adults)
|
|
gptkbp:IUPACName
|
N-(4-hydroxyphenyl)acetamide
|
|
gptkbp:legalStatus
|
OTC (over-the-counter)
|
|
gptkbp:marketedAs
|
1950s
|
|
gptkbp:maximumDailyDose
|
4 grams (adults)
|
|
gptkbp:mechanismOfAction
|
inhibits prostaglandin synthesis
|
|
gptkbp:meltingPoint
|
169°C
|
|
gptkbp:metabolism
|
gptkb:NAPQI
gptkb:paracetamol_glucuronide
gptkb:paracetamol_sulfate
liver
|
|
gptkbp:overdoseTreatment
|
gptkb:acetylcysteine
|
|
gptkbp:pregnancyCategory
|
B (US)
A (Australia)
|
|
gptkbp:prescriptionStatus
|
OTC in most countries
|
|
gptkbp:proteinBinding
|
10–25%
|
|
gptkbp:riskOfOverdose
|
hepatotoxicity
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
rectal
|
|
gptkbp:sideEffect
|
liver damage (in overdose)
|
|
gptkbp:solubility
|
14 mg/mL (20°C)
|
|
gptkbp:synonym
|
acetaminophen
|
|
gptkbp:usedFor
|
pain relief
fever reduction
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:YUZRIZXKGLAOFD-UHFFFAOYSA-N
gptkb:Lamaline
gptkb:Verodine
gptkb:GVGLGOZIDCSQPN-UHFFFAOYSA-N
gptkb:Panadol
gptkb:Parcematone
gptkb:Alaxan
gptkb:GFFGJBXGBJISGV-UHFFFAOYSA-N
gptkb:XSQUKJJJFZCRTK-UHFFFAOYSA-N
gptkb:Valeron
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
paracetamol
|